Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
3. LeMone P. Medical Surgical Nursing: Critical Thinking in Patient Care. 4th ed. Upper Saddle River, NJ: Prentice Hall; 2013.
4. Keolane E, Small L, Walenga J. Rodak's Hematology: Clinical Principles and Applications. New York, NY: Elsevier Health Sciences; 2015.
5. Estlin E. Pediatric Hematology and Oncology: Scientific Principles and Clinical Practice. St. Louis, MO: Wiley; 2010.
6. Koepke J, Lewis S. Hematology: Laboratory Management and Practice. New York, NY: Taylor and Francis; 2015.
7. Price SA. Pathophysiology: Clinical Concepts of Disease Processes. 7th ed. St. Louis, MO: Mosby; 2014.
8. Hudson J. A Study Guide of Clinical Hematology: Theory and Practice. New York, NY: F.A. Davis Company; 2014.
10. Wahed A, Dasgulpta A. Hematology and Coagulation: A Comprehensive Review for Board Preparation, Certification and Clinical Practice. New York, NY: Elsevier Science; 2015.
14. Lux SE, Stossel TP. Blood: Principles and Practice of Hematology. Philadelphia, PA: Lippincott, Williams & Wilkins; 2012.
15. Hoffman R. Hematology: Basic Principles and Practice. New York, NY: Elsevier Health Sciences; 2012.
16. Hillman RS. Hematology in Clinical Practice. 5th ed. New York, NY: McGraw Hill Professional Publishing; 2014.
17. Kellerman RD, Heidelbaugh JJ (eds). Conn's Current Therapy 2025. 1st ed. New York, NY: Elsevier; 2024.
19. Hoffman R, Stilberstein LE. Hematology: Basic Principles and Practice. New York, NY: Elsevier Health Science; 2014.
21. Brashers VL. Clinical Applications of Pathophysiology: Assessment, Diagnostic Reasoning and Management. 2nd ed. St. Louis, MO: Mosby; 2012.
22. Handlin RI. Blood: Principles and Practice of Hematology. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2014.
23. Heckner F. Practical Microscopic Hematology: A Manual for the Clinical Laboratory and Clinical Practice. Philadelphia, PA: Lippincott, Williams and Wilkins; 2012.
24. Gulanick M. Nursing Care Plans: Diagnoses, Interventions, and Outcomes. 10th ed. New York, NY: Elsevier Health Sciences; 2021.
25. Ferrell BR. Oxford Textbook of Palliative Nursing. 5th ed. Oxford: Oxford University Press; 2019.
26. Makic MBF, Martinez-Kratz MR (eds). Ackley and Ladwig's Nursing Diagnosis Handbook: An Evidence-Based Guide to Planning Care. 13th ed. St. Louis, MO: Mosby; 2022.
28. Dean L. Blood Groups and Red Cell Antigens. Bethesda, MD: National Center for Biotechnology Information; 2005.
29. National Health System. Blood Groups. Available at https://www.nhs.uk/conditions/blood-groups. Last accessed September 25, 2025.
30. Duncan J. Pre-Transfusion Testing. Available at https://professionaleducation.blood.ca/en/transfusion/clinical-guide/pre-transfusion-testing. Last accessed September 25, 2025.
31. Gonsorcik V, Zhou L. Rh Typing: Overview: Clinical Indications/Applications, Test Performance and Limitations. Available at https://emedicine.medscape.com/article/1731214-overview. Last accessed September 25, 2025.
32. Westhoff CM, Storry JR, Shaz BH. Human blood group antigens and antibodies. In: Hoffman R, Benz EJ, Silberstein LE, et al. (eds). Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018.
33. National Health System. The RH System. Available at https://www.blood.co.uk/why-give-blood/demand-for-different-blood-types/the-rh-system. Last accessed September 25, 2025.
34. Basavarajegowda A, Shastry S. Pretransfusion Testing. Treasure Island, FL: StatPearls Publishing; 2023.
35. Winnipeg Diagnostic Services. Immunohematology Referral Testing Services Red Cell Antibody Investigation SPECIMEN and REQUISITION REQUIREMENTS Specimen(S). Available at https://www.blood.ca/sites/default/files/MB_REF-01_0.pdf. Last accessed September 25, 2025.
36. Michigan Medicine. Antibody Identification. Available at https://mlabs.umich.edu/tests/antibody-identification. Last accessed September 25, 2025.
37. Tormey CA, Hendrickson JE. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood. 2019;133(17):1821-1830.
38. Wardrop KJ. Transfusion medicine. In: Morgan RV (ed). Handbook of Small Animal Practice. Philadelphia, PA: Saunders; 2008: 707-713.
39. Giri D. Cross Matching: Types, Principle, Procedure and Interpretation. Available at https://laboratorytests.org/cross-matching. Last accessed September 25, 2025.
40. American Society of Hematology. Blood Basics. Available at https://www.hematology.org/education/patients/blood-basics. Last accessed September 25, 2025.
41. American Red Cross. Blood Components. Available at https://www.redcrossblood.org/donate-blood/how-to-donate/types-of-blood-donations/blood-components.html. Last accessed September 25, 2025.
42. Pretini V, Koenen MH, Kaestner L, et al. Red blood cells: chasing interactions. Front Physiol. 2019;10:945.
43. Kuhn V, Diederich L, Keller TCS 4th, et al. Red blood cell function and dysfunction: redox regulation, nitric oxide metabolism, anemia. Antioxid Redox Signal. 2017;26(13):718-742.
44. Dean L. Blood Groups and Red Cell Antigens. Bethesda, MD: National Center for Biotechnology Information; 2005.
45. National Health Service. What is Plasma? Available at https://www.blood.co.uk/plasma/what-is-plasma. Last accessed September 25, 2025.
46. University of Rochester Medical Center. What Are Red Blood Cells? Available at urmc.rochester.edu/encyclopedia/content?ContentTypeID=160&ContentID=34. Last accessed September 25, 2025.
47. International Society of Blood Transfusion. Plasma Transfusion. Available at https://www.isbtweb.org/resources/educational-modules-on-clinical-use-of-blood/plasma-transfusion.html. Last accessed September 25, 2025.
48. National Cancer Institute. NCI Dictionary of Cancer Terms: Platelet. Available at https://www.cancer.gov/publications/dictionaries/cancer-terms/def/platelet. Last accessed September 25, 2025.
49. Karpac C. Platelets. Available at https://ouhsc.edu/platelets/platelets/platelets%20intro.html. Last accessed September 25, 2025.
50. International Society of Blood Transfusion. Platelet Transfusion. Available at https://www.isbtweb.org/isbt-working-parties/clinical-transfusion/resources/patient-blood-management-resources/7-platelet-transfusion.html. Last accessed September 25, 2025.
51. National Health System. Cryoprecipitate Transfusion: Guideline for Practice. Available at http://www.pch-pathlab.com/cms/sites/default/files/documents/Cryoprecipitate%20Transfusion%20-%20Guideline%20for%20Practice.pdf. Last accessed September 25, 2025.
52. LexiDrug. Available at https://online.lexi.com. Last accessed September 25, 2025.
54. University of Texas Medical Branch at Galveston. Cryoprecipitate. Available at https://www.utmb.edu/bloodbank/cryoprecipitate. Last accessed September 25, 2025.
55. Canadian Blood Services. Granulocyte Transfusion Therapy. Available at https://professionaleducation.blood.ca/en/transfusion/clinical-guide/granulocyte-transfusion-therapy. Last accessed September 25, 2025.
57. Nickel B, Gorski L, Kleidon T, et al. Infusion therapy standards of practice, 9th edition. Journal of Infusion Nursing. 2024;47(1S):S1-S285.
58. Perry AG, Potter PA, Ostendorf WR, Laplante N. Clinical Nursing Skills and Techniques. 11th ed. Elsevier Health Sciences; 2024.
60. Wasserman L, Berlin NI, Berk PD. Polycythemia Vera and the Myeloproliferative Disorders. New York, NY: Elsevier Health Science; 2015.
61. McCance KL, Huether SE. Pathophysiology: The Biologic Basis for Disease in Adults and Children. 8th ed. New York, NY: Mosby; 2018.
62. Mitchell R, Kumar V, Abbas AK, Aster JC. Pocket Companion to Robbins & Coltran Pathologic Basis of Disease. 10th ed. New York, NY: Elsevier; 2023.
63. Reich PP. Hematology: Physiopathology Basis for Clinical Practice. New York, NY: Little, Brown & Company; 2008.
64. Gregory TB. Chronic pain perspectives: sickle cell disease: gaining control over the pain. J Fam Pract. 2012;61(9 Suppl):S5-S8.
65. Centers for Disease Control and Prevention. Sickle Cell Disease. Available at https://www.cdc.gov/sickle-cell/about/index.html. Last accessed September 25, 2025.
66. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference Statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148(12):932-938.
67. World Health Organization. Sickle-Cell Anaemia. Available at http://apps.who.int/gb/archive/pdf_files/WHA59/A59_9-en.pdf. Last accessed September 25, 2025.
68. Centers for Disease Control and Prevention. Sickle Cell Disease: What is Sickle Cell Trait? Available at https://www.cdc.gov/sickle-cell/sickle-cell-trait/index.html. Last accessed September 25, 2025.
69. McClish DK, Smith WR, Dahman BA, et al. Pain site frequency and location in sickle cell disease: the PiSCES project. Pain. 2009;145(1-2):246-251.
70. Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood. 2011;118(5):1197-1207.
71. Taylor LE, Stotts NA, Humphreys J, Treadwell MJ, Miaskowski C. A review of the literature on the multiple dimensions of chronic pain in adults with sickle cell disease. J Pain Symptom Manage. 2010;40(3):416-435.
72. National Heart, Lung, and Blood Institute. What Is Sickle Cell Disease? Available at https://www.nhlbi.nih.gov/health/sickle-cell-disease. Last accessed September 25, 2025.
73. LexiDrug. Available at https://online.lexi.com. Last accessed September 25, 2025.
74. National Heart, Lung, and Blood Institute. Sickle Cell Disease: Treatment. Available at https://www.nhlbi.nih.gov/health/sickle-cell-disease/treatment. Last accessed September 25, 2025.
75. U.S. Food and Drug Administration. FDA is Alerting Patients and Health Care Professionals About the Voluntary Withdrawal of Oxbryta From the Market Due to Safety Concerns. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due#. Last accessed September 25, 2025.
76. Pfizer. Press Release. Pfizer Voluntary Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA (voxelotor) From Worldwide Markets. Available at https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease. Last accessed September 25, 2025.
77. Bodhise P, Dejoie M, Brandon Z, Simpkins S, Ballas S. Non-pharmacological management of sickle cell pain. Hematology. 2004;9(3):235-237.
78. National Heart, Lung and Blood Institute. Thalassemias. Available at https://www.nhlbi.nih.gov/health/thalassemia. Last accessed September 25, 2025.
80. Available at https://rarediseases.info.nih.gov/diseases/6639/hereditary-spherocytosis. Last accessed September 25, 2025.
82. British Committee for Standards in Haematology. Guidelines for the Diagnosis and Management of Hereditary Spherocytosis. Available at https://www.gloshospitals.nhs.uk/media/documents/BCSH_Guidelines_for_Hereditary_Spherocytosis.pdf. Last accessed September 25, 2025.
90. Rezende SM, Neumann I, Angchaisuksiri P, et al. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology. J Thromb Haemost. 2024;22(9):2629-2652.
91. U.S. Food and Drug Administration. FDA Approves Expanded Use of Vonvendi for von Willebrand Disease, Including for Certain Uses for Children. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-vonvendi-von-willebrand-disease-including-certain-uses-children. Last accessed September 25, 2025.
92. National Heart, Lung and Blood Institute. Aplastic Anemia. Available at https://www.nhlbi.nih.gov/health/anemia/aplastic-anemia. Last accessed September 25, 2025.
93. National Institute of Diabetes and Digestive and Kidney Diseases. Aplastic Anemia and Myelodysplastic Syndromes. Available at https://www.niddk.nih.gov/health-information/blood-diseases/aplastic-anemia-myelodysplastic-syndromes. Last accessed September 25, 2025.
95. National Institutes of Health, Office of Dietary Supplements. Dietary Supplement Fact Sheet: Vitamin B12. Available at https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional. Last accessed September 25, 2025.
97. Shahidi, Nasrollah T. Aplastic Anemia and Other Bone Marrow Failure Syndromes. New York, NY: Springer; 2015.
98. Killip S, Bennett JM, Chambers MD. Iron deficiency anemia. Am Fam Physician. 2007;75(5):671-678.
99. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153(1):307-323.
100. Lanier JB, Park JJ, and Callahan RC. Anemia in older adults. Am Fam Physician. 2018;98:437-442.
102. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005;118(10):1142-1147.
103. Brooks M. FDA Approves Injectafer for Iron Deficiency Anemia. Available at https://www.medscape.com/viewarticle/808800. Last accessed September 25, 2025.
104. Auerbach M, DeLoughery TG. Treatment of the Adult with Iron Deficiency Anemia. Available at https://www.uptodate.com/contents/treatment-of-anemia-due-to-iron-deficiency. Last accessed September 25, 2025.
106. Singh B. Disseminated Intravascular Coagulation. New York, NY: Nova Science Publication, Inc.; 2013.
107. Grossman SC, Ports CM. Porth's Pathophysiology: Concepts of Altered Health States. Philadelphia, PA: Lippincott, Williams and Wilkins; 2014.
110. Pui C. Acute lymphoblastic leukemia. In: Pui CH (ed). Childhood Leukemias. 3rd ed. New York, NY: Cambridge University Press; 2012.
111. Gale K, Ford AM, Repp R, et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA. 1997;94(25):13950-13954.
112. Ford A, Bennett CA, Price CM, et al. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci USA. 1998;95(8):4584-4588.
113. National Cancer Institute. Childhood Cancer Data Initiative. National Childhood Cancer Registry Explorer. Available at https://nccrexplorer.ccdi.cancer.gov/application.html. Last accessed September 25, 2025.
114. Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Hematol Oncol Clin N Am. 2010;24(1):35-63.
115. Rubnitz JE, Inaba H, Ribeiro RC. Acute myeloid leukemia. In: Pui CH (ed). Childhood Leukemias. 3rd ed. New York, NY: Cambridge University Press; 2012.
116. Young G, Toretsky JA, Campbell AB, Eskenazi AE. Recognition of common childhood malignancies. Am Fam Phys. 2000;61(7):2144-2154.
117. National Cancer Institute. Childhood Acute Lymphoblastic Leukemia Treatment (PDQ). Available at https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq. Last accessed September 25, 2025.
119. Patte C, Auperin A, Michon J, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370-3379.
120. Brown P, Hunger SP, Smith FO, Carroll WL, Reaman GH. Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Rev Hematol. 2009;2(9):145.
121. Cancer Network. FDA Approves Imatinib (Gleevec) for Pediatric ALL. Available at https://www.cancernetwork.com/view/fda-approves-imatinib-gleevec-pediatric-all. Last accessed September 25, 2025.
122. National Cancer Institute. Acute Myeloid Leukemia Treatment (PDQ)–Health Professional Version. Available at https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq. Last accessed September 25, 2025.
123. National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version. Available at https://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq. Last accessed September 25, 2025.
124. National Cancer Institute. Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version. Available at https://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq. Last accessed September 25, 2025.
125. Hutchison RE, Uner A. Biology and pathology of Hodgkin's disease. In: Weinstein HJ, Hudson MM, Link MP (eds). Pediatric Lymphomas. Berlin: Springer; 2007: 7-18.
126. Weijie L (ed). Leukemia: Chapter 1: The 5th Edition of the World Health Organizationn Classification of Hematolymphoid Tumors. Brisbane, AU: Exon Publications; 2022.
127. Lukes R, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966;26:1063-1081.
128. National Cancer Institute. Rye Classification for Hodgkin Disease. Available at https://training.seer.cancer.gov/lymphoma/abstract-code-stage/morphology/rye.html. Last accessed September 25, 2025.
129. Hudson M, Schwartz C, Constine LS. Treatment of pediatric Hodgkin lymphoma. In: Weinstein HJ, Hudson MM, Link MP (eds). Pediatric Lymphomas. Berlin: Springer; 2007: 35-66.
130. Merck Manual Online. Hodgkin Lymphoma. Available at https://www.merckmanuals.com/professional/hematology-and-oncology/lymphomas/hodgkin-lymphoma. Last accessed September 25, 2025.
131. Carbone P, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31(11):1860-1861.
133. Ratkin G, Presant CA, Weinerman B, Reinhard EH. Correlation of anemia with infradiaphragmatic involvement in Hodgkin's disease and other malignant lymphomas. Can Med Assoc J. 1974;111(9):924-927.
134. King DR, Patrick LE, Ginn-Pease ME, McCoy KS, Klopfenstein K. Pulmonary function is compromised in children with mediastinal lymphoma. J Pediatr Surg. 1997;32(2):294-299, 299-300.
136. Terezakis SA, Metzger ML, Hodgson DC, et al. ACR Appropriateness Criteria: pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2014;61(7):1305-1312.
137. National Cancer Institute. Childhood Hodgkin Lymphoma Treatment (PDQ). Available at https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq. Last accessed September 25, 2025.
138. Domino FJ. The 5-Minute Clinical Consult Standard 2025. Philadelphia, PA: Lippincott, Williams & Wilkins; 2024.
139. Perkins S, Morris SW. Biology and pathology of pediatric non-Hodgkin lymphoma. In: Weinstein HJ, Hudson MM, Link MP (eds). Pediatric Lymphomas. Berlin: Springer; 2007: 91-140.
140. Magrath I. B-cell lymphoma/Burkitt lymphoma. In: Weinstein HJ, Hudson MM, Link MP (eds). Pediatric Lymphomas. Berlin: Springer; 2007: 141-174.
141. Sandlund JT. Precursor B and precursor T-cell lymphoblastic lymphoma. In: Weinstein HJ, Hudson MM, Link MP (eds). Pediatric Lymphomas. Berlin: Springer; 2007: 199-213.
142. Reiter A. Anaplastic large-cell lymphoma. In: Weinstein HJ, Hudson MM, Link MP (eds). Pediatric Lymphomas. Berlin: Springer; 2007: 175-197.
143. National Cancer Institute. Childhood Non-Hodgkin Lymphoma Treatment (PDQ). Available at https://www.cancer.gov/types/lymphoma/hp/child-nhl-treatment-pdq. Last accessed September 25, 2025.
144. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105(3):948-958.
145. Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141(6):840-847.
146. Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol. 2010;28(19):3115-3121.
147. Barth MJ, Goldman S, Smith L, et al. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. Br J Haematol. 2013;162(5):678-683.
148. Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2013;27(5):1174-1177.
149. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736-2743.
150. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773-2780.
151. Shah D. Multiple Myeloma: Clinical Presentation. Available at https://emedicine.medscape.com/article/204369-clinical. Last accessed September 25, 2025.
154. Laubach JP. Multiple Myeloma: Clinical Features, Laboratory Manifestations, and Diagnosis. Available at https://www.uptodate.com/contents/multiple-myeloma-clinical-features-laboratory-manifestations-and-diagnosis. Last accessed September 25, 2025.
155. Durie BGM. Multiple Myeloma: Cancer of the Bone Marrow. Concise Review of Relapsed and Refractory Myeloma: 2023 Edition. Available at https://issuu.com/international-myeloma-foundation/docs/concise-review-en? Last accessed September 25, 2025.
156. National Cancer Institute. Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ). Available at https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq. Last accessed September 25, 2025.
157. American Cancer Society. Multiple Myeloma. Available at https://www.cancer.org/cancer/multiple-myeloma.html. Last accessed September 25, 2025.
158. Barrick MC, Mitchell SA. Multiple myeloma: recent advances for this common plasma cell disorder. AJN. 2001;101:6-12.
159. Goldschmidt H, Lannert H, Bommer J, Ho AD. Multiple myeloma and renal failure. Nephrol Dial Transplant. 2000;15(3):301-304.
160. Yarbro CH, Wujcik D, Gobel BH. Cancer Nursing: Principles and Practice. 8th ed. Boston, MA: Jones and Bartlett Publishers; 2016.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.